Tesamorelin 10mg GHRH Analogue | Visceral Adiposity & Metabolic Research Peptide
Tesamorelin 10mg GHRH Analogue | Visceral Adiposity & Metabolic Research Peptide
Tesamorelin 10mg GHRH Analogue | Visceral Adiposity & Metabolic Research Peptide
Overview Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH), structurally based on the native 44-amino acid hypothalamic peptide with a stabilising trans-3-hexenoyl modification at the N-terminus. The 10mg presentation is engineered for advanced research into endogenous GH release, visceral adipose tissue biology, and lipid metabolism.
Mechanism of Interest Tesamorelin acts on pituitary GHRH receptors to stimulate the synthesis and pulsatile release of endogenous growth hormone, in turn elevating circulating IGF-1. The N-terminal modification confers enhanced enzymatic stability — extending half-life and bioavailability compared with native GHRH. Tesamorelin is unique among GHRH analogues in being one of the most extensively researched peptides specifically in the context of visceral adipose tissue (VAT) reduction, hepatic lipid handling, and cardiometabolic markers.
Product Specifications
- Product Name: Tesamorelin 10mg
- Catalogue Reference: TES10-024
- Class: GHRH Analogue (stabilised hexenoyl-modified GRF 1-44)
- Molecular Formula: C₂₂₁H₃₆₆N₇₂O₆₇S
- Molecular Weight: ~5135.9 g/mol
- Purity: ≥98% (HPLC verified)
- Presentation: Lyophilised solid
- Storage: -20°C
Research Applications Tesamorelin is utilised across endocrinology, metabolic, and longevity research — particularly in studies investigating visceral fat reduction, hepatic steatosis and NAFLD models, lipid profiles, IGF-1 dynamics, cognitive markers in ageing populations, and broader GH-axis modulation. Its enhanced stability and pituitary specificity make it one of the more refined GHRH-class research peptides available.
Comparative Research Context Tesamorelin is frequently studied alongside other GHRH analogues such as CJC-1295 (with or without DAC) in comparative research models. Where CJC-1295 with DAC is investigated for its extended albumin-bound action, Tesamorelin is typically explored for its defined pulsatile profile and well-characterised effects on adipose and metabolic endpoints.
Quality & Handling Synthesised under controlled laboratory conditions and supplied as a lyophilised solid for maximum stability. Reconstitution with appropriate bacteriostatic solution is required prior to use in any research model. Every batch is subjected to rigorous quality control to ensure ≥98% purity, identity, and reproducibility.
Compliance Statement All Asclepius peptide products are supplied strictly for laboratory research purposes. They are not intended for human consumption, diagnosis, treatment, or therapeutic use. Enquiries relating to human application cannot be supported.
Order with Confidence Asclepius peptides are sourced, tested, and dispatched to a clinical standard — built for researchers and practitioners who refuse to compromise on integrity, purity, or precision.
For technical specifications, certificates of analysis, or research support, our team is available to assist.